Treatment schedule with an immunoglobulin preparation against fever in granulocytopenic patients with hematological malignancies

• Published in: Japanese Journal of Chemotherapy Vol. 44; no. 11; pp. 853 - 857
• Main Authors: Mori, Kei, Hamada, Kaoru, Imae, Norihisa, Mikasa, Keiichi, Sakamoto, Masahiro, Teramoto, Shoji, Yamanaka, Takayo, Tsujimoto, Masayuki, Maeda, Koichi, Nishikawa, Kiyoshi, Sawaki, Masayoshi, Narita, Nobuhiro, Konishi, Mitsuru
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1996; 公益社団法人 日本化学療法学会
• Subjects: グロブリン製剤; 投与時期; 敗血症; 血液悪性疾患; 顆粒球減少
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.44.853

Patients with hematological malignancies, who were clinically suspected of having sepsis after developing granulocytopenia and a fever of 38°C or higher following anti-cancer chemotherapy, were divided into Group A and Group B by an envelope method. Group A received antibacterial agents (piperacillin: PIPC+isepamicin: ISP) and an immunoglobulin preparation (Polyglobin N®) simultaneously. Group B received antibacterial agents (PIPC+ISP) first and an immunoglobulin preparation 4 days later. The clinical courses of both groups were compared. There were no significant differences between Group A (10 cases) and Group B (11 cases) in underlying diseases and leukocyte count, granulocyte count, CRP or use of CSF preparations at the fever onset. In Group A, decline of fever and improvement of CRP were significantly quicker compared to those in Group B. Recovery of the leukocyte count was also significantly faster in Group A than in Group B. The treatment period with the antibacterial agents was significantly shortened in Group A compared with Group B. Though GOT and GPT were elevated slightly in one case of Group A, no severe adverse reaction was seen in both groups. These results demonstrate the possibility that an early injection of immunoglobulin preparations is effective for the treatment of granulocytopenic infections in patients with hematological malignancies.